导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.91% | 2102/4773 |
| 近一周 | 1.17% | 692/5467 |
| 近一月 | -7.83% | 3610/5421 |
| 近一季 | 19.41% | 80/5238 |
| 近半年 | 3.31% | 1072/4931 |
| 近一年 | -14.35% | 3643/4400 |
| 近两年 | 24.56% | 2515/2954 |
| 近三年 | -17.14% | 2115/2253 |
| 成立以来 | -38.69% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.82% 2503/4961 |
-4.99% 3537/5312 |
- - |
- - |
| 2025 | 5.47% 2997/4813 |
0.43% 1854/3635 |
1.46% 2321/4076 |
20.09% 2034/4524 |
-13.81% 4315/4813 |
| 2024 | -22.88% 2533/3463 |
-17.21% 2574/2808 |
-12.52% 2605/3014 |
20.32% 729/3129 |
-11.51% 3040/3463 |
| 2023 | -20.17% 1866/2656 |
-6.76% 2169/2280 |
-15.24% 2248/2385 |
3.12% 198/2515 |
-2.03% 411/2655 |
| 2022 | -27.12% 1457/2207 |
-9.90% 365/1919 |
-3.47% 1821/2016 |
-23.01% 1951/2113 |
8.84% 254/2208 |
| 2021 | -11.12% 1103/1822 |
-1.20% 449/1255 |
17.59% 183/1330 |
-13.13% 1331/1466 |
-11.94% 1618/1822 |
| 2020 | 70.68% 71/1250 |
16.42% 1/1028 |
42.60% 3/1067 |
3.57% 978/1164 |
-0.74% 1084/1184 |
| 2019 | 56.36% 65/1092 |
32.14% 179/754 |
-3.66% 405/804 |
14.90% 18/850 |
6.89% 527/918 |
| 2018 | -20.90% 203/834 |
- - |
- - |
- - |
-18.82% 658/691 |
| 2017 | 7.46% 319/714 |
- - |
- - |
- - |
- - |
| 2016 | -13.88% 332/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 招商国证生物医药指数(LOF)A VS. 长安沪深300非周期A(740101) |